Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism
- PMID: 3599657
- DOI: 10.1038/ki.1987.125
Renal mass and reserve of vitamin D: determinants in primary hyperparathyroidism
Abstract
We studied circulating 1,25(OH)2D3 and its determinants in 102 patients with primary hyperparathyroidism (PHPT), 33 of them with recurrent renal stones, 60 with non-specific symptoms, and nine with overt bone disease. Means for serum 1,25(OH)2D3 and intestinal absorption of calcium were abnormally high in the renal stone group, slightly elevated in the non-specific group, and low-normal in the bone disease group. In the whole population of patients, we found a positive correlation between circulating 1,25(OH)2D3 and creatinine clearance (taken as an index of the functional renal mass). Negative correlations were observed between 1,25(OH)2D3 and age, and between creatinine clearance and age, the latter being not different from that observed in a normal large population. In the renal stone group, means for the determinants of the renal 1 alpha hydroxylase activity, that is, PTH activity expressed as nephrogenous cyclic AMP (NcAMP), serum phosphate and calcium were identical to those of the group with non-specific symptoms. However means for age were lower and functional renal mass significantly higher in the renal stone group, which may account for the higher value of circulating 1,25(OH)2D3. In the bone disease group, means for age, renal mass and serum calcium were identical to those of the group with non-specific symptoms, and NcAMP was far higher and hypophosphatemia more marked, which may not account for the lower value of circulating 1,25(OH)2D3. However, in the bone disease group, serum 25(OH)D was abnormally low, which may limit the renal production of 1,25(OH)2D3 and explain the low-normal circulating values.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Plasma 1,25-dihydroxyvitamin D levels in primary hyperparathyroidism depend on sex, body mass index, plasma phosphate and renal function.Clin Endocrinol (Oxf). 2007 Jan;66(1):35-42. doi: 10.1111/j.1365-2265.2006.02680.x. Clin Endocrinol (Oxf). 2007. PMID: 17201799
-
Bone aluminum content in predialysis chronic renal failure and its relation with secondary hyperparathyroidism and 1,25(OH)2D3 treatment.Miner Electrolyte Metab. 1989;15(5):295-302. Miner Electrolyte Metab. 1989. PMID: 2811788
-
[Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone].Klin Wochenschr. 1979 Oct 1;57(19):1053-9. doi: 10.1007/BF01479991. Klin Wochenschr. 1979. PMID: 392179 Review. German.
-
Renal mass and serum calcitriol in male idiopathic calcium renal stone formers: role of protein intake.J Clin Endocrinol Metab. 1995 Jun;80(6):1916-21. doi: 10.1210/jcem.80.6.7775641. J Clin Endocrinol Metab. 1995. PMID: 7775641
Cited by
-
Causes and prevention of calcium-containing renal calculi.West J Med. 1991 Sep;155(3):249-52. West J Med. 1991. PMID: 1949770 Free PMC article. Review.
-
Renal manifestations of primary hyperparathyroidism.Indian J Endocrinol Metab. 2012 Mar;16(2):258-62. doi: 10.4103/2230-8210.93745. Indian J Endocrinol Metab. 2012. PMID: 22470864 Free PMC article.
-
The cause of maintained hypercalciuria after the surgical cure of primary hyperparathyroidism is a defect in renal calcium reabsorption.J Endocrinol Invest. 1996 Jan;19(1):12-20. doi: 10.1007/BF03347852. J Endocrinol Invest. 1996. PMID: 8851686 Clinical Trial.
-
A downstream molecule of 1,25-dihydroxyvitamin D3, alpha-1-acid glycoprotein, protects against mouse model of renal fibrosis.Sci Rep. 2018 Nov 26;8(1):17329. doi: 10.1038/s41598-018-35339-x. Sci Rep. 2018. PMID: 30478350 Free PMC article.
-
Brown jaw tumors: today's unusual presentation of primary hyperparathyroidism.J Endocrinol Invest. 2003 Jul;26(7):675-8. doi: 10.1007/BF03347028. J Endocrinol Invest. 2003. PMID: 14594121
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources